Lindblad A S, Novak J W, Nolph K D, Stablein D M, Cutler S J
National CAPD Registry Data Coordinating Center, EMMES Corporation, Potomac, Maryland 20854.
ASAIO Trans. 1988 Apr-Jun;34(2):150-6. doi: 10.1097/00002480-198804000-00013.
The National CAPD Registry has noted encouraging trends in CAPD therapy in the U.S. Recently, trained patients have reported lower peritonitis rates, fewer days hospitalized for dialysis-related events, and lower probability of developing a first episode of a complication. If accumulating experience, better patient selection, and new technologic developments further these trends, then the relatively high transfer rates should begin to decrease since many transfers are related to peritonitis and other complications. The Registry's observations suggest that CAPD is an evolving therapy and that as complication rates and transfer rates decrease, CAPD may play an even greater role in the treatment of patients with end-stage renal disease.
美国国家持续性非卧床腹膜透析登记处注意到美国持续性非卧床腹膜透析（CAPD）治疗出现了令人鼓舞的趋势。最近，训练有素的患者报告称腹膜炎发生率降低、因透析相关事件住院天数减少以及首次发生并发症的可能性降低。如果积累的经验、更好的患者选择和新的技术发展能推动这些趋势，那么相对较高的转归率应该会开始下降，因为许多转归与腹膜炎和其他并发症有关。登记处的观察结果表明，CAPD是一种不断发展的治疗方法，并且随着并发症发生率和转归率的降低，CAPD在终末期肾病患者的治疗中可能会发挥更大的作用。
